The Commission held a seminar to assist public and private hospitals safely implement paediatric versions of the NIMC.
Optimal implementation of the paediatric NIMC will involve use of multi-faceted strategies as part of a co-ordinated implementation program, suited to the needs of local settings.
Appropriate education will form part of an effective implementation program. A range of educational resources is available to support education about safe prescribing and administration of medicines to paediatric patients and optimal use of the paediatric NIMC.
Evaluation using clinically meaningful outcomes is strongly recommended. Selected indicators from the Quality Use of Medicines Indicators in Australian Hospitals (developed by the NSW Therapeutic Advisory Group and Clinical Excellence Commission) are well suited to this purpose. Children’s Hospitals Australasia’s Medication Safety Expert Reference Group recommends using the following indicators as a minimum set to form part of a more comprehensive evaluation of the paediatric NIMC nationally.
Auditing appropriate use of the paediatric NIMC is also recommended at regular intervals to inform optimal implementation locally. A short audit tool (PDF 41 KB) and the standard audit tool (PDF 54 KB) are provided.
Meaningful national comparisons, both locally (across time) and nationally (at any point in time and longitudinally), will only be obtained by standardising audit parameter definitions and by standardising how and by whom data is collected.
It is strongly encouraged that, as a minimum, all facilities using the paediatric NIMC endeavour to achieve maximum adherence with the following core parameters.
Prepared by Madlen Gazarian, Linda Graudins, Sonya Stacey and Joanna Holt, on behalf of Children’s Hospitals Australasia, Medication Safety Expert Reference Group, June 2008
To improve the safety and quality of medicines use nationally, Australian Health Ministers required all public hospitals in Australia to use a common medication chart. The National Inpatient Medication Chart (NIMC) was developed by a multi-disciplinary national working party.
Similarly, a nationally agreed paediatric version has been developed, sharing many features with the original NIMC, but incorporating additional features important for safely using medicines in the paediatric population. Short stay (5 days) and long stay (21 days) versions are available.
Below are a range of education resources for safe prescribing in hospitalised paediatric patients and which will support implementation of the paediatric NIMC. These resources have been developed by multi-disciplinary teams of clinicians (see acknowledgments below) and are designed for use by doctors, nurses and pharmacists.
All facilities caring for paediatric inpatients are invited to use these resources to support the optimal use of the paediatric NIMC for improving paediatric medication safety. We request that you:
Paediatric educational resources
Frequently asked questions
Links to general resources
Let us know whether you found the material useful (and why). Suggestions for improvements are very welcome. Please send your feedback to email@example.com.
This educational package was developed by Dr Madlen Gazarian (Paediatric Clinical Pharmacologist and Head) and Ms Linda Graudins (QUM and Medication Safety Pharmacist), both of the Paediatric Therapeutics Program, University of NSW & Sydney Children’s Hospital, Randwick.
The paediatric resources are based on material originally developed as part of a medication safety improvement program at Sydney Children’s Hospital, with input from the Medication Safety Improvement Project Team and the Adverse Drug Reactions Working Party. Material from NIMC educational resources available through various state and national bodies (see Links to General Resources) have been incorporated, including material developed by the Pharmacy Department, Children, Youth and Women’s Health Service, Adelaide (Lauren Cortis), whose input is gratefully acknowledged. Multi-disciplinary input from clinicians (including nurse educators, senior pharmacists and Chief Resident Medical Officer) at Sydney Children’s Hospital informed the development of the final package.
This package has been reviewed and approved by members of Children’s Hospitals Australasia’s Medication Safety Expert Reference Group to support the optimal use of the paediatric NIMC and to improve paediatric medication safety. Their contribution is gratefully acknowledged. June 2008.